Nuria Pedreño-Lopez

Nuria Pedreño-Lopez

Auto-generated profile, based on publicly available information

Nuria Pedreño-Lopez

AIDS Research Institute

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DMDiogo M. Magnani
Diogo M. Magnani
TRThomas F. Rogers
Thomas F. Rogers
NBNathan Beutler
Nathan Beutler
MRMichael J. Ricciardi
Michael J. Ricciardi
VBVarian K. Bailey
Varian K. Bailey
DWDavid I. Watkins
David I. Watkins
Neutralizing antibodies prevent Zika infection in nonhuman primates.

29 March 2023 in Science Translational Medicine
Verified
Journal Article
Open access
MRMichael J. Ricciardi
Michael J. Ricciardi
LRLauren N. Rust
Lauren N. Rust
NPNuria Pedreño-Lopez
Nuria Pedreño-Lopez
SYSofiya Yusova
Sofiya Yusova
SBSreya Biswas
Sreya Biswas
Benjamin BurwitzBenjamin Burwitz
Benjamin Burwitz
Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine hesitancy, supply deficits, and distribution difficulties leave specific populations at risk of severe YFV disease, as evidenced by recent outbreaks in South America. To establish a treatment for patients with severe YFV infection, we tested 37 YFV-specific monoclonal antibodies isolated from vaccinated humans and identified two capable of potently neutralizing multiple pathogenic primary YFV isolates. Using both hamster and nonhuman primate models of lethal YFV infection, we demonstrate that a single administration of either of these two potently neutralizing antibodies during acute infection fully controlled viremia and prevented severe disease and death in treated animals. Given the potential severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing YFV cases during outbreaks.

6 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FZFangzhu Zhao
Fangzhu Zhao
ZBZachary T. Berndsen
Zachary T. Berndsen
NPNuria Pedreño-Lopez
Nuria Pedreño-Lopez
ABAlison Burns
Alison Burns
JAJoel D. Allen
Joel D. Allen
DSDevin Sok
Devin Sok
SIVmac239 infection of macaques is a favored model of human HIV infection. However, the SIVmac239 envelope (Env) trimer structure, glycan occupancy, and the targets and ability of neutralizing antibodies (nAbs) to protect against SIVmac239 remain unknown. Here, we report the isolation of SIVmac239 nAbs that recognize a glycan hole and the V1/V4 loop. A high-resolution structure of a SIVmac239 Env trimer-nAb complex shows many similarities to HIV and SIVcpz Envs, but with distinct V4 features and an extended V1 loop. Moreover, SIVmac239 Env has a higher glycan shield density than HIV Env that may contribute to poor or delayed nAb responses in SIVmac239-infected macaques. Passive transfer of a nAb protects macaques from repeated intravenous SIVmac239 challenge at serum titers comparable to those described for protection of humans against HIV infection. Our results provide structural insights for vaccine design and shed light on antibody-mediated protection in the SIV model.

1 October 2017 in Molecular Therapy
Verified
Journal Article
Open access
DMDiogo M. Magnani
Diogo M. Magnani
MRMichael J. Ricciardi
Michael J. Ricciardi
VBVarian K. Bailey
Varian K. Bailey
MGMartin J. Gutman
Martin J. Gutman
NPNúria Pedreño-Lopez
Núria Pedreño-Lopez
DWDavid I. Watkins
David I. Watkins
Development of vaccines against mosquito-borne Flaviviruses is complicated by the occurrence of antibody-dependent enhancement (ADE), which can increase disease severity. Long-term delivery of neutralizing antibodies (nAbs) has the potential to effectively block infection and represents an alternative to vaccination. The risk of ADE may be avoided by using prophylactic nAbs harboring amino acid mutations L234A and L235A (LALA) in the immunoglobulin G (IgG) constant region. Here, we used recombinant adeno-associated viruses (rAAVs) to deliver the anti-dengue virus 3 (DENV3) nAb P3D05. While the administration of rAAV-P3D05-rhesus immunoglobulin G1 (rhIgG1)-LALA to rhesus macaques engendered DENV3-neutralizing activity in serum, it did not prevent infection. The emergence of viremia following DENV3 challenge was delayed by 3-6 days in the rAAV-treated group, and replicating virus contained the envelope mutation K64R. This neutralization-resistant variant was also confirmed by virus outgrowth experiments in vitro. By delivering P3D05 with unmutated Fc sequences, we further demonstrated that DENV3 also evaded wild-type nAb prophylaxis, and serum viral loads appeared to be higher in the presence of low levels of unmutated P3D05-rhIgG1. Our study shows that a vectored approach for long-term delivery of nAbs with the LALA mutations is promising, but prophylaxis using a single nAb is likely insufficient at preventing DENV infection and replication.

30 September 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
LGLucas Gonzalez-Nieto
Lucas Gonzalez-Nieto
ICIsabelle M Castro
Isabelle M Castro
GBGeorg F Bischof
Georg F Bischof
YSYoung C Shin
Young C Shin
MRMichael J Ricciardi
Michael J Ricciardi
MMMauricio A Martins
Mauricio A Martins
A prophylactic vaccine against human immunodeficiency virus (HIV) remains a top priority in biomedical research. Given the failure of conventional immunization protocols to confer robust protection against HIV, new and unconventional approaches may be needed to generate protective anti-HIV immunity. Here we vaccinated rhesus macaques (RMs) with a recombinant (r)DNA prime (without any exogenous adjuvant), followed by a booster with rhesus monkey rhadinovirus (RRV)−a herpesvirus that establishes persistent infection in RMs (Group 1). Both the rDNA and rRRV vectors encoded a near-full-length simian immunodeficiency virus (SIVnfl) genome that assembles noninfectious SIV particles and expresses all nine SIV gene products. This rDNA/rRRV-SIVnfl vaccine regimen induced persistent anti-Env antibodies and CD8+ T-cell responses against the entire SIV proteome. Vaccine efficacy was assessed by repeated, marginal-dose, intrarectal challenges with SIVmac239. Encouragingly, vaccinees in Group 1 acquired SIVmac239 infection at a significantly delayed rate compared to unvaccinated controls (Group 3). In an attempt to improve upon this outcome, a separate group of rDNA/rRRV-SIVnfl-vaccinated RMs (Group 2) was treated with a cytotoxic T-lymphocyte antigen-4 (CTLA-4)-blocking monoclonal antibody during the vaccine phase and then challenged in parallel with Groups 1 and 3. Surprisingly, Group 2 was not significantly protected against SIVmac239 infection. In sum, SIVnfl vaccination can protect RMs against rigorous mucosal challenges with SIVmac239, a feat that until now had only been accomplished by live-attenuated strains of SIV. Further work is needed to identify the minimal requirements for this protection and whether SIVnfl vaccine efficacy can be improved by means other than anti-CTLA-4 adjuvant therapy. Given the remarkable immune evasion properties of human immunodeficiency virus (HIV), unorthodox vaccine approaches might be needed to elicit protective anti-HIV immunity. Here we investigated whether vaccination with a near-full-length simian immunodeficiency virus (SIVnfl) genome could protect rhesus macaques (RMs) against pathogenic SIV challenge. To deliver SIVnfl, we used a DNA prime followed by a booster with a herpesvirus that establishes persistent infection in RMs. SIVnfl vaccinees developed long-lasting antibodies against the SIV Envelope protein and T-cell responses against the entire SIV proteome. Encouragingly, SIVnfl vaccinees were significantly protected against intrarectal challenge with SIVmac239, a feat that until now had only been accomplished by live-attenuated strains of SIV. Curiously, combining the aforementioned vaccine regimen with immune checkpoint blockade did not result in protection against SIVmac239 infection in a separate group of RMs. Vaccination with inactivated immunodeficiency virus genomes should, therefore, be considered as a potential strategy for eliciting anti-HIV immunity.

27 February 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
CUCarla Usai
Carla Usai
EAErola Ainsua-Enrich
Erola Ainsua-Enrich
VUVíctor Urrea
Víctor Urrea
EPEdwards Pradenas
Edwards Pradenas
CLCristina Lorca-Oró
Cristina Lorca-Oró
JSJoaquim Segalés
Joaquim Segalés
Age is associated with reduced efficacy of vaccines and linked to higher risk of severe COVID-19. Here we determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation. Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion and production of neutralising antibodies; however, animals were only partially protected from weight loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while tissue lesion development was not altered. In GSH, the shortest interval between immunisation and inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing RNA in nasal turbinates; viral nucleoprotein amount decreased in both tissues. In mice, immunisation was able to improve the survival of infected animals. Despite the high protection shown in young animals, S-29 efficacy was reduced in the geriatric population. Our research highlights the importance of testing vaccine efficacy in older animals as part of preclinical vaccine evaluation.